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| BACKG ROU N D
gastrointestinal toxicity through Oxo. 4, 5 It is currently approved for the treatment of gastric, colorectal, head and neck, breast, pancreatic, bile tract, and non-small cell lung cancers in Japan.
Of note, 5-fluorouracil is mainly eliminated by the liver and excreted as expiratory CO 2 . Therefore, in general, there is no requirement for dose adjustment in patients with renal impairment. In contrast, CDHP is predominantly excreted in urine. 4 Hence, lower CDHP clearance in patients with renal impairment leads to greater inhibition of DPD activity, higher plasma concentrations of 5-fluorouracil and an increased incidence of toxicity. 5 Therefore, the dose of S-1 is usually determined on the basis of body surface area (BSA) and adjusted according to renal function. A post-marketing survey of S-1 involving 3294 patients with advanced gastric cancer in Japan demonstrated a close relationship between the incidence of grade 3 or worse hematological toxicity and renal function. 6 This survey recommended that S-1 doses be reduced in patients with impaired renal function to prevent the occurrence of adverse reactions.
6
Although the prescribing information for S-1 recommends a reduction in its dose to manage adverse reactions in patients with impaired renal function, there are no prospective pharmacokinetic and safety studies conducted in this setting. The aim of the present study was to prospectively investigate the pharmacokinetic profiles of 5-fluorouracil and CDHP, and to evaluate the recommended dose modification of S-1 in patients with renal impairment. 
| MATERIAL AND ME THODS

| Patient eligibility
| Study design
This prospective study was conducted at 3 institutions in Japan (Kobe University Hospital, Shimane University Hospital and National
Cancer Center Hospital).
The primary objective of this study was to evaluate the steadystate pharmacokinetic parameters of 5-fluorouracil and CDHP on day 8 of treatment in patients with various degrees of renal function receiving S-1. The eGFR and BSA were used to adjust the dose of S-1 and the appropriateness of this approach was determined. The secondary objective was to evaluate toxicity, including nausea, vomiting, oral stomatitis, diarrhea and myelosuppression.
The study protocol was approved by the review board of each participating institution. The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki.
Written informed consent was obtained from each participant.
| Treatment and assessment of treatment
We used the Japanese eGFR equation 7 7 The eGFR has been widely accepted as a reliable and simple method for estimating GFR in medical practice in Japan. Although the eGFR equation was developed based on data obtained from Japanese patients with chronic kidney disease (CKD), it offers higher accuracy for predicting GFR than the CGF and MDRD in cancer patients prior to and after treatment with cisplatin.
15
The eGFR was calculated using the following formula: eGFR (mL/min/1
.73 m (Table 1) .
S-1 was administered orally twice daily for more than 14 consecutive days. The dose was adjusted based on the patient's BSA (as stated in the prescribing information in Japan) and modified according to renal function (Table 1 
| Pharmacokinetic evaluation and analysis
Blood samples were collected on day 8, when CDHP was considered to be at a steady state. This was based on the terminal half-life of 5-fluorouracil and CDHP being approximately 2.9 ± 1.1 and 4.2 ± 1.4 hours, respectively, after 28-day consecutive administration. 4 Samples were obtained prior to administration and at 0.5, 1, 2, 4, 6 and 8 hours after administration by drawing 5 mL of blood into heparin-containing tubes. Plasma was separated within 30 minutes through centrifugation at 1500 g for 10 minutes at 4°C and stored at −80°C until analysis. Plasma concentrations of 5-fluorouracil, CDHP, tegafur and Oxo were determined using a liquid and gas chromatography-tandem mass spectrometry assay (FALCO Biosystems) as previously described by Matsushima et al. 16 The lower limit of quantification for each com- 
| Statistical analysis
As in previous pharmacokinetic studies, we considered that 6-8 patients per cohort were sufficient for the evaluation of pharmacokinetics. The target number of patients in each cohort was set at 10.
Pharmacokinetic parameters were compared among cohorts using Dunnett's test. Patient characteristics and AE in each cohort were compared using Fisher's exact test. The correlation between the clearance of CDHP or AUC of 5-fluorouracil and eGFR was determined using the Pearson product-moment correlation coefficient. All statistical analyses were performed using the JMP (SAS Institute, version 11.2.0).
| RE SULTS
| Patient characteristics
A total of 33 Japanese patients were enrolled from September 2010
to June 2014 and classified into 4 cohorts according to renal function (Table 1) . Patient characteristics are summarized in Table 2 and 
| Pharmacokinetics
Mean values of pharmacokinetic parameters for CDHP, 5-fluorouracil, tegafur and Oxo on day 8 are presented in Table 3 (Table 3 and Figure S2B , r 2 = 0.36, P = 0.0002) and was significantly decreased in cohorts 3 and 4 compared with that reported in cohort 1 ( Figure S2C , P = 0.0048 and P = 0.0027, respectively). In addition, clearance of CDHP was also correlated with clearance of creatinine ( Figure S2D ). The number in each column indicates the actual number of patients enrolled in each cohort. BSA, body surface area; eGFR, estimated glomerular filtration rate.
TA
| Toxicity
The toxicity profiles during the first 15 days of administration are summarized in Table 4 . The frequency and severity of AE were similar among the different cohorts. However, the frequency of decreased platelet count tended to be higher in cohort 3 compared to cohort 1.
In addition, there was no difference observed among cohorts in the frequency of S-1 dose suspension or reduction. Toxicities of CTCAE grade 3 and 4 accounted for 20%-30% of all toxicities reported in each cohort.
TA B L E 2 Patient characteristics (median [range])
Number of patients state. 4 In contrast, previous studies performed sampling for pharmacokinetics on the first day of S-1 administration, prior to CHDP reaching a steady state. [18] [19] [20] Moreover, previous studies included few patients with moderate or severe renal dysfunction. 5, 18, 19 In clinical practice, S-1 is administered twice daily for 14 or 28 days.
| D ISCUSS I ON
Thus, we suggest that the pharmacokinetics of S-1 observed in repeated dosing are more meaningful with regard to safety than those observed in single dosing. In this study, we enrolled 33 pa- impaired renal function, they did not evaluate toxicities, and prospective validation of the formula is required. In our study, we prospectively evaluated the dosing strategy of S-1 in patients with impaired renal function with regard to pharmacokinetics as well as toxicity.
The eGFR was developed to determine the severity of renal dysfunction in non-cancer patients with CKD, 7 rather than in cancer patients or for dose adjustment purposes. However, in the present study, cancer patients with renal dysfunction were adequately treated with S-1 using a dosing strategy based on the eGFR and BSA. There are various approaches to the assessment of renal function. The objective standard is direct measurement using an extraneous substance, which is completely filtered by the glomeruli and does not undergo protein binding, metabolism, secretion or reabsorption at the renal tubular level. 8 However, for example, the measurement of GFR using inulin requires repeated blood sampling, substantial consumption of water and repeated punctual urination. These complications have hampered the measurement of GFR using extraneous substances in clinical settings.
Other methods, using SCr, have also been developed. However, use of SCr to estimate the GFR is problematic because the level of SCr is affected by various factors, such as muscle mass, nutritional condition, ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; PLT, platelet count; SCr, serum creatinine; WBC, white blood cell counts.
tubular secretion and diet. 21 The CGF is a classical method commonly used to estimate renal function. 12 However, this method was developed based on data obtained from Caucasian populations. Moreover, because the SCr was measured using the Jaffe method rather than the enzymatic method or isotope dilution mass spectrometry, the renal function may have been overestimated. For these reasons, the National Institutes of Health issued a recommendation for creatinine standardization. 22 The MDRD 13 and CKD-EPI 14 equations are currently used to estimate GFR in United States. Similarly, in Japan, the eGFR equation was developed for patients with CKD, offering accurate estimations of the GFR in cancer patients even during chemotherapy with cisplatin. 15, 23 In addition, there was no significant difference in the frequency or severity of AE among the cohorts and the toxicity profile in this study was similar to those previously reported (Table 4) .
Our study has several limitations. First, only 3 patients with severe renal impairment were included in cohort 4. Second, it was not possible to prospectively assess the efficacy of S-1 in patients with renal dysfunction due to the inclusion of patients with various types of cancer. Third, it was not possible to assess the intra-day and interday variation in our study. Finally, polymorphisms of CYP2A6 (*4A, *7 and *9), which play a role in the biotransformation of tegafur to 5-fluorouracil, were not assessed.
In conclusion, we performed a prospective pharmacokinetic study of S-1 in patients with different levels of renal function. The results showed that patients with lower renal function maintained adequate plasma concentrations of 5-fluorouracil. Furthermore, there were no significant differences observed among the cohorts in the occurrence of AE. Therefore, we propose that the dose adjustment of S-1 used in this study for patients with impaired renal function is useful in clinical practice.
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